Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
| Product | Cell Type | Engineered Functionality | Indication | R&D | PreClinical | Clinical | Collaboration |
|---|---|---|---|---|---|---|---|
| iPSC-derived Cell Products – Hematologic Malignancies | |||||||
| FT516 | iNK | hnCD16 | AML | ||||
| FT516 | iNK | hnCD16 | BCL + mAb | ||||
| FT596 | iNK | hnCD16 + IL15-RF + CAR19 | BCL and CLL ± mAb | ||||
| FT538 | iNK | hnCD16 + IL15-RF + CD38-KO | AML | ||||
| FT538 | iNK | hnCD16 + IL15-RF + CD38-KO | MM + mAb | ||||
| FT576 | iNK | hnCD16 + IL15-RF + CD38-KO + CAR-BCMA | MM ± mAb | ||||
| FT819 | iT | TRAC-targeted CAR19 + TCR-KO | Hematologic Malignancies | ||||
| iPSC-derived Cell Products – Advanced Solid Tumors | |||||||
| FT500 | iNK | Non-engineered | Advanced Solid Tumors + CPB | ||||
| FT516 | iNK | hnCD16 | Advanced Solid Tumors + mAb | ||||
| FTxxx | iNK and iT | Multiplexed engineered CAR-MICA/B | Advanced Solid Tumors | ||||
| iPSC-derived Cell Products – Cancer Immunotherapy Collaborations | |||||||
| Janssen | iNK and iT | Multiplexed engineered CAR-targeted | Up to 4 cancer antigens |  |
|||
| ONO | iT | Multiplexed engineered CAR-targeted | Up to 2 cancer antigens |  |
|||
| iPSC-derived Cell Products – Immune Disorders | |||||||
| FT301 | iMDSC | Multiplexed engineered | Not disclosed | ||||
| Donor-derived Cell Products | |||||||
| ProTmune™ | Hematopoietic graft | Small molecule modulated (non-engineered) | Hematologic Malignancies | ||||
iPSC = induced pluripotent stem cell iNK = iPSC-derived NK cell iT = iPSC-derived T cell iMDSC = iPSC-derived myeloid-derived suppressor cell hnCD16 = high-affinity, non-cleavable CD16 Fc receptor IL15-RF = IL-15/IL-15 receptor fusion CD38-KO = CD38 knock-out CAR = chimeric antigen receptor mAb = monoclonal antibody CPB = checkpoint blockade therapy AML = Acute myelogenous leukemia BCL = B-cell lymphoma CLL = Chronic lymphocytic leukemia MM = Multiple myeloma